Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
about
Therapeutic Drug Monitoring of Posaconazole: an UpdateEmerging issues with diagnosis and management of fungal infections in solid organ transplant recipientsClinical hepatotoxicity associated with antifungal agents.Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous HemofiltrationIn Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderInternational Evaluation of MIC Distributions and Epidemiological Cutoff Value (ECV) Definitions for Fusarium Species Identified by Molecular Methods for the CLSI Broth Microdilution Method.Pharmacologic and clinical evaluation of posaconazole.Posaconazole: a review of the gastro-resistant tablet and intravenous solution in invasive fungal infections.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.New facets of antifungal therapy.Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.Posaconazole: An Update of Its Clinical Use.Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.
P2860
Q26746016-139E0464-6F14-4B78-AC5B-48CD9229B753Q28084643-FB7D9859-1C5F-4E90-A366-3AEBA662182DQ34546811-6C8819FF-B517-4BA7-A8AA-E0DA5C1A507CQ34596761-D1D5BB17-A4B2-4AF7-8F64-71F3BB46DF15Q36076106-26782E7D-6AB0-4057-A4B1-957C0158B2BEQ36290764-7E1EAB9C-76C1-49FC-8667-95AE2CF33F96Q36571990-92798B47-2F8B-413C-87D1-08C22F2626F6Q37445943-CC7FEFFC-6AED-424B-97ED-5B950B3BAF16Q38321383-92CE5258-AB84-434D-A77B-5BFB4391B8B9Q38341595-A3DA712C-11E2-4C30-A34E-F97E8E4BA466Q38534865-60A8456D-2C49-4FEC-B907-3377DBBD43F0Q38681635-742A2392-C636-43C9-A9C8-C310F1F6C758Q38797864-CB1BC8A9-12E5-4F37-9B32-0ACF72FD730AQ40577292-B0095CDE-0E8B-4124-94C3-D6F7FB513BDEQ41175826-65CBD31C-60D6-47E0-8CB0-70FFDEA127DCQ41993016-614A7118-3A65-4CFC-8F8C-9AEF476D605DQ42144246-91375BB1-7642-4EDA-A39C-450F58709D14Q42563983-CC55913B-FCC5-42EF-A853-F466290DAACCQ54243380-47A6D0A0-1710-47E4-B194-45E813A9680FQ55236793-3C082B56-0850-419E-B1B9-0490441A27D3
P2860
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@ast
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@en
type
label
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@ast
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@en
prefLabel
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@ast
Phase 1B study of the pharmaco ...... k for invasive fungal disease.
@en
P2093
P2860
P356
P1476
Phase 1B study of the pharmaco ...... sk for invasive fungal disease
@en
P2093
Andrew J Ullmann
Gopal Krishna
Hernando Patino
Hetty Waskin
Johan Maertens
Maria Caceres
Michael N Robertson
Nicholas Kartsonis
P2860
P304
P356
10.1128/AAC.02686-13
P407
P577
2014-04-14T00:00:00Z